Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-02-24

Last Posted Date: 2012-01-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT00296062

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

First Posted Date: 2006-02-22

Last Posted Date: 2010-06-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00294931

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 1 locations

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Phase 1

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2006-02-13

Last Posted Date: 2014-05-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT00290719

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

Phase 2

Conditions: Liver Cancer

First Posted Date: 2006-02-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 30

Registration Number: NCT00287976

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧
Children's Hospital - Sheffield, Sheffield, England, United Kingdom
🇬🇧
Childrens Hospital for Wales, Cardiff, Wales, United Kingdom

and more 18 locations

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2006-01-23

Last Posted Date: 2013-02-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00280787

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2006-01-13

Last Posted Date: 2013-06-26

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 35

Registration Number: NCT00276692

Locations: 🇬🇧
Queen's Medical Centre, Nottingham, England, United Kingdom
🇬🇧
Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland

and more 17 locations